First-generation CBP inhibitors are limited by severe thrombocytopenia. TOLREMO's drug has shown no such toxicity in 45 patients, enabling a strategy to pursue the larger, more commercially attractive solid tumor market, rather than being confined to the initial validated indication of multiple myeloma.

Typically, the starting dose in a Phase 1 trial is too low to show efficacy. For CDR Life, observing immunological activity and biomarker improvement in their very first patient was a rare and remarkable event that provided the first tangible sign their scientific platform could become a real therapeutic.

Unlike most trials that avoid patients who failed other therapies, Corvus intentionally included them, considering it a 'stacking deck against yourself'. This high-risk bet, based on their drug's unique mechanism, paid off by showing efficacy in a tough-to-treat population and demonstrating a lack of cross-resistance.

Remix Therapeutics leveraged compelling Phase 1 data in a rare cancer with no approved treatments to accelerate its corporate strategy. Achieving a 43% overall response rate, far exceeding the 15% from prior therapies, provided the clinical validation necessary to pursue a reverse merger and go public.

Actuate employed a master protocol that tested their drug alongside eight different standard-of-care chemotherapies in patients who had already failed them. This design efficiently demonstrated the drug's ability to reverse chemo-resistance across multiple histologies, informing their Phase 2 strategy.

Diakonos chose glioblastoma, the deadliest brain cancer, for its first trial. This counterintuitive strategy provided a faster data readout, powerful validation upon success, and a lower regulatory burden from the FDA—all critical advantages for an early-stage company.

Royvant's success with its PH-ILD drug is not just about the positive data, but its operational velocity. Announcing the initiation of its Phase 3 study simultaneously with the Phase 2 results showcases a "better and faster than pharma" execution model that compresses timelines and builds investor confidence.

To demonstrate its drug could overcome resistance, Actuate designed a trial where patients who had already failed a specific chemotherapy were given the exact same regimen again, but this time with Actuate's drug added. The resulting increased efficacy across eight different cancers provided powerful, direct proof of the drug's mechanism.

While TROP2-ADCs are currently approved for later-line lung cancer treatment, active clinical trials are already evaluating them as a potential replacement for traditional chemotherapy in the first-line setting. This represents a significant strategic ambition to shift the entire treatment paradigm for newly diagnosed patients with both non-small cell and small cell lung cancer.